Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
Ineffective medication can remove the "worst fear" of schizophrenia.
2.
GLP-1 receptor agonists, cancer risk and questionable significance
3.
Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US
4.
Mouse study finds tirzepatide slowed obesity-associated breast cancer growth
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications
2.
CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target
3.
Understanding QSOFA: A Vital Tool for Recognizing Sepsis
4.
The Cutting-Edge of Phlebectomy: Redefining Vein Care
5.
Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
5.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge